Vabysmo Shows Advantages Over Aflibercept in Wet AMD and Diabetic Macular Edema
source: pixabay.com

Vabysmo Shows Advantages Over Aflibercept in Wet AMD and Diabetic Macular Edema

An announcement from the drug company Genentech highlights the results of a recent study which demonstrated that the drug faricimab-svoa (marketed at Vabysmo) was able to dry retinal fluid more…

Continue Reading Vabysmo Shows Advantages Over Aflibercept in Wet AMD and Diabetic Macular Edema
A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer
source: pixabay.com

A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer

    For patients who were given a diagnosis of advanced, inoperable (unresectable) biliary tract cancer, an article appeared in Healio with some encouraging news. Gemcitabine and cisplatin drugs have…

Continue Reading A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer
New Cell Therapy Approved by the FDA to Reduce Risk of Infection After Transplant
source: pixabay.com

New Cell Therapy Approved by the FDA to Reduce Risk of Infection After Transplant

  Omisirge (omidubicel) is the first allogeneic (from a donor) product for SCT that has been the recipient of FDA approval. The FDA's nod moves Omisirge into the realm of…

Continue Reading New Cell Therapy Approved by the FDA to Reduce Risk of Infection After Transplant
Glioblastoma: Current Therapies and Recent Therapeutic Advances
source: pixabay.com

Glioblastoma: Current Therapies and Recent Therapeutic Advances

Republished with permission from Personalize My Medicine, a Patient Worthy partner organization.  Written by Eleanor Doherty Glossary Antibody, Antidepressant, Antigen, Apoptosis, Astrocyte, CAR-T Cell Therapy, Atypia, Clinical Trial, CNS, Dendritic Cell Vaccine, Epidermal Growth Factor, Ex-Vivo, Glioblastoma Multiforme, Glioma, Immunotherapy, Metastasis, Mitotic Activity, Monoclonal Antibody, Necrosis, Neuron, Neurotransmitter, Oncology, Oncolytic Virotherapy, Prognosis, Radiotherapy, Stem Cell, Surgical…

Continue Reading Glioblastoma: Current Therapies and Recent Therapeutic Advances
Advanced Leukemia: Test of Oral Revumenib Brought Impressive Results
source: pixabay.com

Advanced Leukemia: Test of Oral Revumenib Brought Impressive Results

  For patients with refractory or relapsed KMT2A rearrangement or NPM1-mutations, the AUGMENT 101 study of the investigational menin inhibitor revumenib yielded impressive results. According to an article in MedicalXpress,…

Continue Reading Advanced Leukemia: Test of Oral Revumenib Brought Impressive Results
Blinatumomab Immunotherapy is Effective for Infants with Aggressive Acute Lymphoblastic Leukemia (ALL)
192635 / Pixabay

Blinatumomab Immunotherapy is Effective for Infants with Aggressive Acute Lymphoblastic Leukemia (ALL)

  KMT2A rearrangements—a DNA fault—lead to treatment-resistant acute lymphoblastic leukemia (ALL) in infants. While around 50% of children with KMT2A rearrangements respond well to intensive chemotherapy, the remaining 50% do…

Continue Reading Blinatumomab Immunotherapy is Effective for Infants with Aggressive Acute Lymphoblastic Leukemia (ALL)
Compassion Corner: An Honest Account by an Orthopedic Surgeon Who Found the Key to Compassion
source: pixabay.com

Compassion Corner: An Honest Account by an Orthopedic Surgeon Who Found the Key to Compassion

Compassion [kuhm-pash-uhn] noun A feeling of deep sympathy and sorrow for another who is stricken by misfortune, accompanied by a strong desire to alleviate the suffering. Compassion Corner is a…

Continue Reading Compassion Corner: An Honest Account by an Orthopedic Surgeon Who Found the Key to Compassion
Biologics License Application (BLA): Lovo-cel Gene Therapy for SCD Just Submitted 
https://pixabay.com/en/heart-red-blood-cells-erythrocyte-2176218/

Biologics License Application (BLA): Lovo-cel Gene Therapy for SCD Just Submitted 

  As bluebird bio ("bluebird") waited on FDA feedback regarding the manufacturing process for lovotibeglogene autotemcel (lovo-cel) genetherapy, the company disclosed that it would most likely miss its Q1 submission…

Continue Reading Biologics License Application (BLA): Lovo-cel Gene Therapy for SCD Just Submitted 
Experimental Duchenne Muscular Dystrophy Treatment Earns Fast Track Designation
source: shutterstock.com

Experimental Duchenne Muscular Dystrophy Treatment Earns Fast Track Designation

According to a story from PR Newswire, the biopharmaceutical company Avidity Biosciences, Inc., recently announced that its investigational therapy AOC 1044 has received the US Food and Drug Administration's Fast…

Continue Reading Experimental Duchenne Muscular Dystrophy Treatment Earns Fast Track Designation
Nanoparticles Delivering mRNA Gene Editing Solutions to the Lungs Can Combat Genetic Diseases
source: shutterstock.com

Nanoparticles Delivering mRNA Gene Editing Solutions to the Lungs Can Combat Genetic Diseases

  Treatment advances are occurring daily in the field of rare disease. As researchers hone their strategies and tools, new technologies are emerging with the potential to significantly impact patients…

Continue Reading Nanoparticles Delivering mRNA Gene Editing Solutions to the Lungs Can Combat Genetic Diseases